Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
News|Articles|May 1, 2025
Allergy Month in Review: April 2025
Author(s)Chelsie Derman
Advertisement
Advertisement
Although April brought no regulatory changes in allergy medication, various journals published studies on allergy treatments or associations in the allergy field.
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.
Advertisement
Advertisement